|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of liver biopsy in hepatocellular carcinoma显示文摘The role of liver biopsy in the diagnosis of hepatocellular carcinoma(HCC)has been challenged over time by the ability of imaging techniques to characterize liver lesions in patients with known cirrhosis.In fact,in the diagnostic algorithm for this tumor,histology is currently relegated to controversial cases.Furthermore,the risk of complications,such as tumor seeding and bleeding,as well as inadequate sampling have further limited the use of liver biopsy for HCC management.However,there is growing evidence of prognostic and therapeutic information available from microscopic and molecular analysis of HCC and,as the information content of the tissue sample increases,the advantages of liver biopsy might modify the current risk/benefit ratio.We herein review the role and potentiality of liver biopsy in the diagnosis and management of HCC.As the potentiality of precision medicine comes to the management of HCC,it will be crucial to have rapid pathways to define prognosis,and even treatment,by identifying the patients who could most benefit from target-driven therapies.All of the above reasons suggest that the current role of liver biopsy in the management of HCC needs substantial reconsideration. | Luca Di Tommaso Marco Spadaccini Matteo Donadon Nicola Personeni Abubaker Elamin Alessio Aghemo Ana Lleo | 2019 | World Journal of Gastroenterology2019，25，40： | 11 |
| 2 | Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies显示文摘Hepatocellular carcinoma (HCC) develops in the context of environmental risk factors like chronic viral hepatitis, diabetes and alcohol exposure, often associated to an increased risk of cirrhosis. Antiviral treatments that are effective to counteract hepatitis B and C may also attenuate the risk of tumor development. However, since hepatitis B-related carcinogenesis is promoted independently of the onset of cirrhosis, such antiviral treatments as nucleo(t)side analogs can promote regression of cirrhosis, prevent clinical decompensation and variceal bleeding but not HCC. This means that in successfully treated patients with cirrhosis, HCC is often the consequence of their extended survival. In hepatitis C patients, a sustained virological response to interferon-based therapies can reduce the rate of HCC development, even in patients with cirrhosis who experience histological regression of their liver disease. Future therapies aimed at this endpoint in at risk populations should take into consideration pretreatment patient stratification for host, viral and environmental risk factors. In this context the recent discovery of single nucleotide polymorphisms involved in the immune system function and tumorigenesis, might permit enrollment of populations of patients enriched with HCC risk factors for targeted chemopreventive therapies. This could finally pave the way to personalized algorithms, as already seen in the diagnosis and treatment schemes for chemoprevention. | Cristina Della Corte Alessio Aghemo Massimo Colombo | 2013 | World Journal of Gastroenterology2013，19，9： | 4 |
| 3 | A review of the treatment of chronic hepatitis C virus infection in cirrhosis显示文摘 | Elena Vezali Alessio Aghemo Massimo Colombo | 2010 | Clinical Therapeutics2010，，13： | 2 |
| 4 | Osteosarcopenia in autoimmune cholestatic liver diseases:Causes,management,and challenges显示文摘Primary biliary cholangitis and primary sclerosing cholangitis(PSC)are the most common cholestatic liver diseases(CLD)in adults and are both characterized by an immune pathogenesis.While primary biliary cholangitis is a model autoimmune disease,with over 90%of patients presenting very specific autoantibodies against mitochondrial antigens,PSC is considered an immune mediated disease.Osteoporosis is the most common bone disease in CLD,resulting in frequent fractures and leading to significant morbidity.Further,sarcopenia is emerging as a frequent complication of chronic liver diseases with a significant prognostic impact and severe implications on the quality of life of patients.The mechanisms underlying osteoporosis and sarcopenia in CLD are still largely unknown and the association between these clinical conditions remains to be dissected.Although timely diagnosis,prevention,and management of osteosarcopenia are crucial to limit the consequences,there are no specific guidelines for management of osteoporosis and sarcopenia in patients with CLD.International guidelines recommend screening for bone disease at the time of diagnosis of CLD.However,the optimal monitoring strategies and treatments have not been defined yet and vary among centers.We herein aim to comprehensively outline the pathogenic mechanisms and clinical implications of osteosarcopenia in CLD,and to summarize expert recommendations for appropriate diagnostic and therapeutic approaches. | Nicola Pugliese Ivan Arcari Alessio Aghemo Andrea G Lania Ana Lleo Gherardo Mazziotti | 2022 | World Journal of Gastroenterology2022，28，14： | 2 |
| 5 | Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management显示文摘 | Mauro Viganò Elisabetta Degasperi Alessio Aghemo Pietro Lampertico Massimo Colombo | 2012 | Expert Opinion on Biological Therapy2012，，： | 2 |
| 6 | Theeffect of some drugs on the maximal capacity of athleticperformance in man显示文摘 | MARGARIA R AGHEMO P ROVELLI E | 1964 | Internationale Zeitschrift fürangewandte Physiologie einschlie-lich Arbeitsphysiologie1964，20，4： | 1 |
| 7 | Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C 显示文摘 | Aghemo A Rumi MG Colombo M | 2009 | Expert Rev Anti Infect Ther2009，7，8： | 1 |
| 8 | EASL Clinical Practice Guidelines: Management of hepatitis C virus infection显示文摘 | Mutimer D Aghemo A Diepolder H | 2014 | J Hepatol2014，60，2： | 1 |
| 9 | Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C 显示文摘 | Aghemo A De Francesco R | 2015 | Gut2015，64，： | 1 |
| 10 | Hepatitis C virus treatment in the real world: optimising treatment and access to therapies显示文摘 | Zoulim Fabien Liang T Jake Gerbes Alexander L Aghemo Alessio Deuffic-Burban Sylvie Dusheiko Geoffrey Fried Michael W Pol Stanislas Rockstroh Ju?rgen Kurt Terrault Norah A Wiktor Stefan | 2015 | Gut2015，，11： | 1 |
| 11 | Indirect determination of maximal O2 consumption in man显示文摘 | Margaria R Aghemo P Rovelli E | 1965 | J Appl Physical1965，20，5： | 1 |
| 12 | De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C(case study and literature review)显示文摘 | Fabrizi F Aghemo A Moroni G | 2014 | Dig Dis Sci2014，59，3： | 1 |
| 13 | Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection<!-- Doctopic: VH -->显示文摘 | Barbara Oliviero Dalila Mele Elisabetta Degasperi Alessio Aghemo Eleonora Cremonesi Maria Grazia Rumi Carmine Tinelli Stefania Varchetta Stefania Mantovani Massimo Colombo Mario U. Mondelli | 2013 | Journal of Hepatology2013，，1： | 1 |
| 14 | High levels of factor VIII and risk of extra-hepatic portal vein obstruction显示文摘 | Martinelli I Primignani M Aghemo A | 2009 | J Hepatol2009，50，5： | 1 |
| 15 | Contrast-enhanced computed tomography and ultrasound-guided liver biopsy to diagnose dysplastic liver nodules in cirrhosis显示文摘 | Massimo Iavarone Matteo Angelo Manini Angelo Sangiovanni Mirella Fraquelli Laura Virginia Forzenigo Luca Di Tommaso Alessio Aghemo Massimo Roncalli Guido Ronchi Massimo Colombo | 2013 | Digestive and Liver Disease2013，，1： | 1 |
| 16 | Pegylated IFN- alpha2a and riba- virin in the treatment of hepatitis C 显示文摘 | Aghemo A Rumi MG Colombo M | 2009 | Expert Rev Anti Infect Ther2009，7，8： | 1 |
| 17 | The pattern of pegylated interferon-alpha2b and ribavirin treatment failure in cirrhotic patients depends on hepatitis C virus genotype显示文摘 | Aghemo A Rumi MG Monico S | | 0，，04： | 1 |
| 18 | Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C显示文摘 | Aghemo A Rumi MG Colombo M | 2009 | Expert Rev Anti Infect Ther2009，7，8： | 1 |
| 19 | Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C 显示文摘 | Aghemo A Prati GM Rumi MG | 2012 | Hepatology2012，56，5： | 1 |
| 20 | Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection显示文摘 | Marabita F Aghemo A De Nicola S | 2011 | Hepatology2011，54，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员